- Home
- MOBX vs IFRX Comparison
MOBX vs IFRX Comparison
Compare MOBX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- IFRX
- Stock Information
- Founded
- MOBX 2020
- IFRX 2007
- Country
- MOBX United States
- IFRX Germany
- Employees
- MOBX N/A
- IFRX N/A
- Industry
- MOBX
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- IFRX Health Care
- Exchange
- MOBX Nasdaq
- IFRX Nasdaq
- Market Cap
- MOBX 57.1M
- IFRX 53.5M
- IPO Year
- MOBX N/A
- IFRX 2017
- Fundamental
- Price
- MOBX $0.93
- IFRX $1.26
- Analyst Decision
- MOBX
- IFRX Strong Buy
- Analyst Count
- MOBX 0
- IFRX 5
- Target Price
- MOBX N/A
- IFRX $7.40
- AVG Volume (30 Days)
- MOBX 1.7M
- IFRX 963.7K
- Earning Date
- MOBX 08-13-2025
- IFRX 11-07-2025
- Dividend Yield
- MOBX N/A
- IFRX N/A
- EPS Growth
- MOBX N/A
- IFRX N/A
- EPS
- MOBX N/A
- IFRX N/A
- Revenue
- MOBX $10,984,000.00
- IFRX $191,224.00
- Revenue This Year
- MOBX N/A
- IFRX N/A
- Revenue Next Year
- MOBX N/A
- IFRX $1,216.24
- P/E Ratio
- MOBX N/A
- IFRX N/A
- Revenue Growth
- MOBX 180.13
- IFRX 54.36
- 52 Week Low
- MOBX $0.55
- IFRX $0.71
- 52 Week High
- MOBX $2.47
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- MOBX 45.49
- IFRX 50.79
- Support Level
- MOBX $1.00
- IFRX $1.45
- Resistance Level
- MOBX $1.19
- IFRX $1.77
- Average True Range (ATR)
- MOBX 0.16
- IFRX 0.19
- MACD
- MOBX -0.01
- IFRX -0.00
- Stochastic Oscillator
- MOBX 14.17
- IFRX 41.05
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.